Fmr LLC Has Stake in Aclaris Therapeutics Inc (ACRS)
recently revealed that they own 8.7% of Aclaris Therapeutics Inc (NASDAQ:ACRS) in a Form 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, February 13th. The investor owns 2,673,260 shares of the stock worth $52,075,105. The disclosure is available through the SEC website at this hyperlink.
ACRS has been the topic of several research reports. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 target price on shares of Aclaris Therapeutics in a research report on Tuesday, November 7th. Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price on the stock. Zacks Investment Research downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Aclaris Therapeutics currently has a consensus rating of “Hold” and an average price target of $41.80.
Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) traded up $0.38 during trading on Tuesday, reaching $19.48. The company had a trading volume of 196,220 shares, compared to its average volume of 374,037. Aclaris Therapeutics Inc has a 52-week low of $18.46 and a 52-week high of $33.25. The stock has a market capitalization of $586.17, a P/E ratio of -8.84 and a beta of 1.26.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.